FR2330383B1 - - Google Patents

Info

Publication number
FR2330383B1
FR2330383B1 FR7533899A FR7533899A FR2330383B1 FR 2330383 B1 FR2330383 B1 FR 2330383B1 FR 7533899 A FR7533899 A FR 7533899A FR 7533899 A FR7533899 A FR 7533899A FR 2330383 B1 FR2330383 B1 FR 2330383B1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR7533899A
Other versions
FR2330383A1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synthelabo SA
Original Assignee
Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthelabo SA filed Critical Synthelabo SA
Priority to FR7533899A priority Critical patent/FR2330383A1/fr
Priority to US05/734,359 priority patent/US4252984A/en
Priority to ZA766338A priority patent/ZA766338B/xx
Priority to BE171927A priority patent/BE847801A/fr
Priority to DE2649605A priority patent/DE2649605C3/de
Priority to NZ182498A priority patent/NZ182498A/xx
Priority to AT812076A priority patent/AT344683B/de
Priority to NLAANVRAGE7612123,A priority patent/NL179051C/xx
Priority to AR265315A priority patent/AR214303A1/es
Priority to SE7612177A priority patent/SE433208B/xx
Priority to CH1380076A priority patent/CH602582A5/xx
Priority to NO763732A priority patent/NO142034C/no
Priority to GR52068A priority patent/GR61363B/el
Priority to GB45560/76A priority patent/GB1515978A/en
Priority to JP51133144A priority patent/JPS5848543B2/ja
Priority to CA264,650A priority patent/CA1072981A/fr
Priority to FI763132A priority patent/FI62829C/fi
Priority to IL50814A priority patent/IL50814A/xx
Priority to PT65780A priority patent/PT65780B/fr
Priority to DK495476A priority patent/DK145119C/da
Priority to AU19259/76A priority patent/AU501581B2/en
Priority to ES452920A priority patent/ES452920A1/es
Priority to IE2435/76A priority patent/IE43645B1/en
Priority to LU76117A priority patent/LU76117A1/xx
Publication of FR2330383A1 publication Critical patent/FR2330383A1/fr
Priority to US06/020,463 priority patent/US4311708A/en
Application granted granted Critical
Publication of FR2330383B1 publication Critical patent/FR2330383B1/fr
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/24—Ethers with hydroxy compounds containing no oxirane rings with polyhydroxy compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
FR7533899A 1975-11-06 1975-11-06 Nouveaux ethers de phenols substitues, leurs sels, leur preparation et les medicaments qui les renferment Granted FR2330383A1 (fr)

Priority Applications (25)

Application Number Priority Date Filing Date Title
FR7533899A FR2330383A1 (fr) 1975-11-06 1975-11-06 Nouveaux ethers de phenols substitues, leurs sels, leur preparation et les medicaments qui les renferment
US05/734,359 US4252984A (en) 1975-11-06 1976-10-20 Phenol ethers
ZA766338A ZA766338B (en) 1975-11-06 1976-10-25 Phenol ethers
DE2649605A DE2649605C3 (de) 1975-11-06 1976-10-29 p-substituierte 1-Phenoxy-3-amino-2-propanole, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel
BE171927A BE847801A (fr) 1975-11-06 1976-10-29 Ethers de phenols et leur preparation.
FI763132A FI62829C (fi) 1975-11-06 1976-11-02 Foerfarande foer framstaellning av fenoletrar anvaendbara saosom laekemedel
NLAANVRAGE7612123,A NL179051C (nl) 1975-11-06 1976-11-02 Werkwijze ter bereiding van een geneesmiddel met een cardiovasculaire werking, gevormd geneesmiddel en werkwijze ter bereiding van daarvoor geschikte fenoxypropanolaminederivaten.
AR265315A AR214303A1 (es) 1975-11-06 1976-11-02 Un procedimiento para preparar nuevos derivados de(cicloalquilalquiloxi-(o tio,o-sulfonil-alquil)-(o alquiloxi fenoxi)-1amino-3-propanol-2
SE7612177A SE433208B (sv) 1975-11-06 1976-11-02 Forfarande for framstellning av fenoletrar
CH1380076A CH602582A5 (fr) 1975-11-06 1976-11-02
NO763732A NO142034C (no) 1975-11-06 1976-11-02 Analogifremgangsmaate for fremstilling av terapeutisk aktive fenoletere.
GR52068A GR61363B (en) 1975-11-06 1976-11-02 Preparation process of ethers of substituted phenols
NZ182498A NZ182498A (en) 1975-11-06 1976-11-02 Phenol ethers and pharmaceutical compositions
JP51133144A JPS5848543B2 (ja) 1975-11-06 1976-11-02 新規フエノ−ルエ−テル誘導体およびその製造法
CA264,650A CA1072981A (fr) 1975-11-06 1976-11-02 Esters phenoliques
AT812076A AT344683B (de) 1975-11-06 1976-11-02 Verfahren zur herstellung von neuen substituierten 3-phenoxy-2-hydroxy-1-aminopropanen und deren saeureadditionssalzen
IL50814A IL50814A (en) 1975-11-06 1976-11-02 Substituted phenoxy propanolamines,their preparation and pharmaceutical compositions containing them
PT65780A PT65780B (fr) 1975-11-06 1976-11-02 Procede de preparation d'ethers de phenols substitues
DK495476A DK145119C (da) 1975-11-06 1976-11-02 Analogifremgangsmaade til fremstilling af phenolethere eller syreadditionssalte deraf
AU19259/76A AU501581B2 (en) 1975-11-06 1976-11-02 Phenol ethers
ES452920A ES452920A1 (es) 1975-11-06 1976-11-02 Procedimiento para preparar eteres de fenoles.
IE2435/76A IE43645B1 (en) 1975-11-06 1976-11-02 Phenol ethers
GB45560/76A GB1515978A (en) 1975-11-06 1976-11-02 Phenol ethers
LU76117A LU76117A1 (fr) 1975-11-06 1976-11-03
US06/020,463 US4311708A (en) 1975-11-06 1979-03-14 Phenol ethers

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7533899A FR2330383A1 (fr) 1975-11-06 1975-11-06 Nouveaux ethers de phenols substitues, leurs sels, leur preparation et les medicaments qui les renferment

Publications (2)

Publication Number Publication Date
FR2330383A1 FR2330383A1 (fr) 1977-06-03
FR2330383B1 true FR2330383B1 (fr) 1979-09-21

Family

ID=9162099

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7533899A Granted FR2330383A1 (fr) 1975-11-06 1975-11-06 Nouveaux ethers de phenols substitues, leurs sels, leur preparation et les medicaments qui les renferment

Country Status (24)

Country Link
US (2) US4252984A (fr)
JP (1) JPS5848543B2 (fr)
AR (1) AR214303A1 (fr)
AT (1) AT344683B (fr)
AU (1) AU501581B2 (fr)
BE (1) BE847801A (fr)
CA (1) CA1072981A (fr)
CH (1) CH602582A5 (fr)
DE (1) DE2649605C3 (fr)
DK (1) DK145119C (fr)
ES (1) ES452920A1 (fr)
FI (1) FI62829C (fr)
FR (1) FR2330383A1 (fr)
GB (1) GB1515978A (fr)
GR (1) GR61363B (fr)
IE (1) IE43645B1 (fr)
IL (1) IL50814A (fr)
LU (1) LU76117A1 (fr)
NL (1) NL179051C (fr)
NO (1) NO142034C (fr)
NZ (1) NZ182498A (fr)
PT (1) PT65780B (fr)
SE (1) SE433208B (fr)
ZA (1) ZA766338B (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2409980A1 (fr) * 1977-11-24 1979-06-22 Synthelabo Ethers de phenols et leur application en therapeutique
IT1147311B (it) * 1980-02-13 1986-11-19 Stabil Bioterapico Farmachim Eteri basici di 4-idrossi-benzofenoni con attivita' quali agenti betabloccanti e relativi procedimento di preparazione
ZW9881A1 (en) * 1980-06-02 1981-12-23 Hoffmann La Roche Substituted phenoxyaminopropanol derivatives
DE3125870C2 (de) * 1980-07-09 1994-09-15 William John Louis 3-Aminopropoxyphenyl Derivate, ihre Herstellung und sie enthaltende Arzneimittel
CH643527A5 (en) * 1980-10-24 1984-06-15 Ciba Geigy Ag Process for the preparation of 1-alkylamino-3-(4-(2-lower alkoxy-ethyl)phenoxy)-2-propanols
JPS57108047A (en) * 1980-11-06 1982-07-05 Sandoz Ag 3-aminopropoxyphenyl derivative, manufacture and pharmaceutical composition containing same
FI76551C (fi) 1980-11-06 1988-11-10 Sandoz Ag Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 3-aminopropoxifenylderivat.
US5347050A (en) * 1980-11-06 1994-09-13 Richard Berthold 3-aminopropoxyphenyl derivatives, their preparation and pharmaceutical compositions containing them
DE3125636A1 (de) * 1981-06-30 1983-01-13 Merck Patent Gmbh, 6100 Darmstadt 1-(p-2-isopropoxyethoxymethyl-phenoxy)-3-isopropylamino-propan-2-ol zur senkung des augeninnendrucks und ophtalmikum, enthalten diese verbindung
FR2512443A1 (fr) * 1981-09-10 1983-03-11 Synthelabo Derives de phenoxy-3 propanol-2, leur preparation et leur application en therapeutique
DE3151201A1 (de) * 1981-12-23 1983-07-28 Beiersdorf Ag, 2000 Hamburg Substituierte phenoxyalkanolamine und phenoxyalkanol-cycloalkylamine, verfahren zu ihrer herstellung, diese verbindungen enthaltende pharmazeutische zubereitungen und zwischenprodukte
US4450172A (en) * 1982-03-10 1984-05-22 E. I. Du Pont De Nemours And Company Antihypertensive polyhalohydroxyisopropyl phenylalka(e)noic acid esters of alkylaminohydroxypropyloxyphenylalkyl alcohols
FR2536390B1 (fr) * 1982-11-22 1986-03-21 Synthelabo Isomere s du betaxolol, sa preparation et son application en therapeutique
CA1262729A (fr) * 1983-10-19 1989-11-07 Leo Alig Phenoxypropanolamines
US5166218A (en) * 1983-10-19 1992-11-24 Hoffmann-La Roche Inc. Phenoxypropanolamines and pharmaceutical compositions thereof
ZA852843B (en) * 1984-05-15 1985-11-27 Warner Lambert Co Bevantolol preparation
GB8412864D0 (en) * 1984-05-19 1984-06-27 Smith Kline French Lab Chemical compounds
US5554367A (en) * 1984-10-31 1996-09-10 Alcon Laboratories, Inc. Compositions for treatment of glaucoma
ES8609190A1 (es) * 1985-02-07 1986-07-16 Pharma Investi S A Un procedimiento para preparar eteres fenolicos
US5095151A (en) * 1985-05-21 1992-03-10 American Home Products Corporation Preparation of propranolol hydrochloride macrocrystals
EP0252007A3 (fr) * 1986-06-28 1989-07-05 Ciba-Geigy Ag Dérivés de 2-propanol comme inhibiteurs de corrosion
US4694022A (en) * 1986-12-24 1987-09-15 Alcon Laboratories, Inc. Fatty acid salts of betaxolol useful in the treatment of glaucoma
DE3866984D1 (en) * 1987-07-21 1992-01-30 Hoffmann La Roche Phenoxypropanolamine.
FR2672594B1 (fr) * 1991-02-08 1994-07-01 Synthelabo Derives d'ethers de phenols, leur preparation et leur application en therapeutique.
ATE263137T1 (de) 1995-10-10 2004-04-15 William John Louis 3-aminopropoxyphenyl-derivate
CA2193149C (fr) * 1995-12-22 2002-04-23 David H. Donabedian Systemes cationiques therapeutiques
US5942633A (en) * 1996-06-19 1999-08-24 Abbott Laboratories Process for the selective alkylation of betaxolol intermediates
US5731463A (en) * 1996-09-23 1998-03-24 Abbott Laboratories Selective alkylation of an alcohol substituted phenol compound
CA2330611A1 (fr) 1998-05-22 1999-12-02 The Board Of Trustees Of The Leland Stanford Junior University Molecules bifonctionnelles et therapies basees sur celles-ci
US6258350B1 (en) 1999-01-20 2001-07-10 Alcon Manufacturing, Ltd. Sustained release ophthalmic formulation
US7081482B2 (en) * 1999-11-30 2006-07-25 Alcon, Inc. Use of β-adrenoceptor antagonists for the manufacture of a medicament for the treatment of disorders of the outer retina
EP1303306B1 (fr) * 2000-07-27 2006-06-21 Pharmacia Corporation Polytherapie par antagoniste d'aldosterone epoxy-steroidien et antagoniste beta-adrenergique pour le traitement de l'insuffisance cardiaque congestive
ATE445838T1 (de) 2001-07-25 2009-10-15 Raptor Pharmaceutical Inc Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
US7001615B1 (en) 2001-12-07 2006-02-21 Alcon, Inc. Sustained release ophthalmic, otic and nasal suspension
GEP20074134B (en) 2002-08-19 2007-06-25 Pfizer Prod Inc Combination therapy for hyperproliferative diseases
NZ543741A (en) * 2003-05-30 2009-10-30 Ranbaxy Lab Ltd Substituted pyrrole derivatives and their use as HMG-Co inhibitors
CN1300079C (zh) * 2004-12-03 2007-02-14 南京大学 合成4－[2－(环丙基甲氧基)乙基]苯酚的新工艺
EP2671508B1 (fr) 2005-04-28 2020-09-16 Proteus Digital Health, Inc. Système pharma-informatique
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US8026377B2 (en) * 2005-11-08 2011-09-27 Ranbaxy Laboratories, Limited Process for (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
AR059838A1 (es) * 2006-03-14 2008-04-30 Ranbaxy Lab Ltd Formulaciones para dosis estabilizantes de estatina
WO2008010087A2 (fr) * 2006-07-14 2008-01-24 Ranbaxy Laboratories Limited FORMES POLYMORPHES D'UN INHIBITEUR DE LA HMG-CoA-RÉDUCTASE ET LEURS UTILISATIONS
US20080161324A1 (en) * 2006-09-14 2008-07-03 Johansen Lisa M Compositions and methods for treatment of viral diseases
CA2663377A1 (fr) 2006-09-18 2008-03-27 Raptor Pharmaceutical Inc. Traitement des troubles hepatiques par l'administration de conjugues de proteine associee au recepteur (rap)
ATE547394T1 (de) 2006-12-01 2012-03-15 Bristol Myers Squibb Co N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf- erkrankungen
US7964613B2 (en) 2007-02-28 2011-06-21 Asahi Kasei Pharma Corporation Sulfonamide compound
WO2008112287A1 (fr) 2007-03-12 2008-09-18 Nektar Therapeutics Conjugués d'oligomère bêtabloquant
US8987262B2 (en) 2007-10-19 2015-03-24 Universite de Bordeaux Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas
EP2050441A1 (fr) 2007-10-19 2009-04-22 Université Victor Segalen Bordeaux 2 Utilisation de bêtabloquants pour la fabrication d'un médicament pour le traitement d'hémangiomes
JP2009040769A (ja) * 2008-07-09 2009-02-26 William John Louis ３−アミノ−プロポキシフェニル誘導体（ｉ）
HUE059078T2 (hu) 2009-02-20 2022-10-28 Enhanx Biopharm Inc Glutation-alapú hatóanyagszállító rendszer
JP2012526144A (ja) 2009-05-06 2012-10-25 ラボラトリー スキン ケア インコーポレイテッド 活性物質−リン酸カルシウム粒子複合体を含む経皮送達組成物およびその使用方法
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
SG11201507496UA (en) 2013-04-17 2015-11-27 Pfizer N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
WO2016055901A1 (fr) 2014-10-08 2016-04-14 Pfizer Inc. Composés d'amide substitué
SG11202107614PA (en) 2019-01-18 2021-08-30 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT323131B (de) * 1935-11-15 1975-06-25 Boehringer Sohn Ingelheim Verfahren zur herstellung von neuen racemischen oder optisch aktiven n,n'-bis-(3-subst.phenoxy-2-hydroxy-1-propyl)-alpha,omega-diaminoalkanen sowie deren saureadditionssalzen
GB1078852A (en) * 1964-09-30 1967-08-09 Ici Ltd Alkanolamine derivatives
CA956632A (en) * 1969-05-16 1974-10-22 Yoshitomi Pharmaceutical Industries Phenoxy-aminopropanol derivatives
SE372762B (fr) * 1969-05-21 1975-01-13 Haessle Ab
US3712890A (en) * 1969-06-20 1973-01-23 Ici Ltd Process for making 2-aryloxymethyl morpholines
SE354851B (fr) * 1970-02-18 1973-03-26 Haessle Ab
GB1458392A (en) * 1973-11-09 1976-12-15 Ici Ltd Optically-active 1-aryloxy-2,3-epoxypropane derivatives

Also Published As

Publication number Publication date
CA1072981A (fr) 1980-03-04
DE2649605A1 (de) 1977-05-18
AR214303A1 (es) 1979-05-31
ES452920A1 (es) 1977-11-01
DK495476A (da) 1977-05-07
DE2649605B2 (de) 1980-07-10
SE7612177L (sv) 1977-05-07
NO142034C (no) 1980-06-18
AT344683B (de) 1978-08-10
FR2330383A1 (fr) 1977-06-03
NO142034B (no) 1980-03-10
FI62829C (fi) 1983-03-10
IL50814A0 (en) 1977-01-31
AU1925976A (en) 1978-05-11
FI763132A (fr) 1977-05-07
NL7612123A (nl) 1977-05-10
DK145119B (da) 1982-09-06
IL50814A (en) 1979-11-30
NZ182498A (en) 1978-04-03
GR61363B (en) 1978-10-30
ZA766338B (en) 1977-10-26
LU76117A1 (fr) 1978-07-10
PT65780A (fr) 1976-12-01
DK145119C (da) 1983-02-14
US4311708A (en) 1982-01-19
ATA812076A (de) 1977-12-15
NO763732L (no) 1977-05-09
JPS5285146A (en) 1977-07-15
NL179051B (nl) 1986-02-03
PT65780B (fr) 1978-05-10
IE43645L (en) 1977-05-06
IE43645B1 (en) 1981-04-22
SE433208B (sv) 1984-05-14
CH602582A5 (fr) 1978-07-31
GB1515978A (en) 1978-06-28
NL179051C (nl) 1986-07-01
AU501581B2 (en) 1979-06-21
US4252984A (en) 1981-02-24
JPS5848543B2 (ja) 1983-10-28
BE847801A (fr) 1977-02-14
FI62829B (fi) 1982-11-30
DE2649605C3 (de) 1981-04-02

Similar Documents

Publication Publication Date Title
FR2330383B1 (fr)
JPS573489B2 (fr)
FR2308127B1 (fr)
JPS5514961Y2 (fr)
JPS5526613B2 (fr)
JPS5341673B2 (fr)
JPS51128001U (fr)
JPS51162638U (fr)
IN143393B (fr)
CH599987A5 (fr)
CH599677A5 (fr)
CH606702A5 (fr)
CH601099A5 (fr)
CH606837A5 (fr)
CH605165A5 (fr)
LU74353A1 (fr)
CH606700A5 (fr)
CH603184A5 (fr)
CH602938A5 (fr)
CH600619A5 (fr)
CH606595A5 (fr)
CH600318A5 (fr)
CH595954A5 (fr)
CH601890A5 (fr)
CH606207A5 (fr)

Legal Events

Date Code Title Description
CL Concession to grant licences
CC Supplementary protection certificate (spc) laid open to the public (law of 25 june 1990)

Free format text: 92C0060, 920402

CB Supplementary protection certificate (spc) granted (law of 25 june 1990)

Free format text: 92C0060, 751106

CL Concession to grant licences